1. Opioid use disorders: HHS needs measures to assess the effectiveness of efforts to expand access to medication-assisted treatment : report to majority leader, U.S. Senate Publication: Washington, DC : United States Government Accountability Office, October 2017 Subject(s): Health Services AccessibilityOpiate Substitution TreatmentOpioid-Related Disorders -- drug therapyOutcome Assessment (Health Care)Community-Institutional RelationsBuprenorphine -- therapeutic useInservice TrainingInsurance CoverageMethadone -- therapeutic useNaloxone -- therapeutic useNaltrexone -- therapeutic usePrescription Drug Diversion -- prevention & controlHumansUnited StatesUnited States. Department of Health and Human Services.
2. Early changes in waivered clinicians and utilization of buprenorphine for opioid use disorder after implementation of the 2021 HHS Buprenorphine Practice Guidelines Publication: Washington, D.C. : U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, December 2, 2022 Subject(s): Buprenorphine -- therapeutic useDrug Prescriptions -- statistics & numerical dataDrug Utilization -- statistics & numerical dataDrug Utilization -- trendsOpioid-Related Disorders -- drug therapyPractice Guidelines as TopicScope of PracticeUnited StatesUnited States. Department of Health and Human Services.
3. Opioid use disorder: developing depot buprenorphine products for treatment Publication: Silver Spring, MD : Center for Drug Evaluation and Research, February 2019 Subject(s): Buprenorphine -- therapeutic useDrug DevelopmentOpioid-Related Disorders -- drug therapyBuprenorphine -- administration & dosageClinical Trials as TopicDelayed-Action PreparationsNarcotic AntagonistsOpiate Substitution TreatmentHumansUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.